Skip to main content

Table 6 Change in physician global assessment of disease activity, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

 

Categories of change in physician global assessment of disease activity

 

> +10 (n = 8)

+10 to -10 (n = 44)

-11 to -20 (n = 33)

-21 to -40 (n = 56)

< -40 (n = 43)

F

p-value

PRO Instruments

       

SF-36

       

Physical functioning

-5.6 (27.9)

1.6 (13.2)

2.7 (12.6)

10.1 (19.5)

14.3 (19.7)

4.8

0.0010

Role physical

-8.9 (13.0)

1.8 (17.7)

6.3 (19.4)

11.2 (21.2)

21.0 (25.9)

6.4

0.0001

Bodily pain

-6.6 (13.4)

-0.8 (15.7)

6.4 (18.8)

14.3 (14.2)

22.2 (22.3)

12.3

0.0000

General health

-5.9 (17.2)

-1.2 (14.7)

4.2 (12.4)

3.6 (14.6)

8.5 (13.3)

3.4

0.0097

Vitality

0.0 (13.8)

-3.1 (18.5)

1.9 (19.7)

7.4 (13.8)

20.7 (22.1)

10.3

0.0000

Social functioning

-15.6 (23.8)

-3.1 (24.1)

0.0 (22.9)

8.7 (19.9)

16.7 (30.9)

5.7

0.0003

Role emotional

-10.4 (25.5)

-3.4 (23.7)

1.9 (22.9)

7.7 (24.6)

13.3 (28.9)

3.4

0.0109

Mental health

-8.1 (13.1)

-4.0 (15.4)

5.0 (16.2)

4.0 (16.7)

14.5 (19.7)

7.6

0.0000

Physical summary

-1.8 (8.0)

1.0 (4.9)

1.9 (4.9)

4.5 (5.9)

6.5 (7.8)

6.7

0.0000

Mental summary

-4.8 (10.5)

-.27 (9.2)

1.1 (8.9)

2.4 (8.6)

7.5 (12.8)

6.5

0.0001

HAQ-DI

0.03 (0.44)

0.05 (0.33)

-0.14 (0.36)

-0.28 (0.41)

-0.54 (0.53)

9.1

0.0000

FACIT-Fatigue

-4.7 (5.5)

-0.6 (7.8)

2.5 (7.1)

4.1 (6.2)

9.6 (7.2)

14.8

0.0000